Breaking MYC metabolism

The metabolic enzyme phosphoribosyl pyrophosphate synthetase 2 could represent a tractable way to modulate the notoriously undruggable oncogene MYC.1 The findings from a University of California, San Francisco team are licensed to Effector Therapeutics Inc. and provide a clue as to how the company plans to attack protein translation-related mechanisms in cancers.

The UCSF group now plans to identify specific inhibitors of phosphoribosyl pyrophosphate synthetase 2 (PRPS2) and wants to see if the mechanism is present in cancers promoted by oncogenes other than MYC (c-Myc).

MYC is a transcription factor that tumors hijack to upregulate the metabolic machinery that promotes DNA and protein synthesis, glycolysis and glutaminolysis.2 The problem is that

Read the full 1091 word article

How to gain access

Continue reading with a
two-week free trial.